Published • loading... • Updated
Anvisa Approves New Medicine for Pulmonary Hypertension; Learn More
Summary by CNN Brasil
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
The National Agency for Health Surveillance (Anvisa) has granted registration for a new medicine for the treatment of adult patients with pulmonary hypertension associated with interstitial pulmonary disease (HP-DPI). Approval represents a significant milestone for a group of patients who, until then, did not have specific therapeutic options registered in Brazil for this condition. The [...]
·Brazil
Read Full Article
Tyvaso is indicated for patients with pulmonary hypertension associated with interstitial lung disease and still depends on the price definition to reach the market
·São Paulo, Brazil
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
